Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00751556 · ClinicalTrials.gov registry record · Phase 1
Single/Multiple Dose Bioavailability Trial
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00751556 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 32 participants.
The verdict
NCT00751556, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
To determine the pharmacokinetic profile of an extended release tablet of naproxen sodium 660 mg relative to the established commercial Aleve 220 mg tablet following single dose administration and at steady-state following multiple dose administration for 4 days.
Interventions
- DRUG Naproxen Sodium 660mg
- DRUG Commercial Aleve 220 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00751556
The ClinicalTrials.gov registry entry for NCT00751556 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Naproxen Sodium 660mg is the first listed.
NCT00751556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00751556 about?
NCT00751556 is a clinical study titled "Single/Multiple Dose Bioavailability Trial". To determine the pharmacokinetic profile of an extended release tablet of naproxen sodium 660 mg relative to the established commercial Aleve 220 mg tablet following single dose administration and at steady-state following multiple dose administration for 4 days.
What is the current status of trial NCT00751556?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2008-02. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00751556?
The interventions under investigation include: Naproxen Sodium 660mg (DRUG), Commercial Aleve 220 mg (DRUG).
Who is sponsoring clinical trial NCT00751556?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.